Piramal Pharma Statistics

Total Valuation

Piramal Pharma has a market cap or net worth of INR 276.32 billion. The enterprise value is 319.68 billion.

Market Cap	276.32B
Enterprise Value	319.68B

Important Dates

The next estimated earnings date is Monday, July 28, 2025.

Earnings Date	Jul 28, 2025
Ex-Dividend Date	Jul 16, 2025

Share Statistics

Current Share Class	1.33B
Shares Outstanding	n/a
Shares Change (YoY)	+4.41%
Shares Change (QoQ)	+7.88%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	611.07M

Valuation Ratios

The trailing PE ratio is 303.22 and the forward PE ratio is 146.74.

PE Ratio	303.22
Forward PE	146.74
PS Ratio	3.02
PB Ratio	3.40
P/TBV Ratio	6.84
P/FCF Ratio	121.24
P/OCF Ratio	30.97
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.06, with an EV/FCF ratio of 140.26.

EV / Earnings	350.79
EV / Sales	3.49
EV / EBITDA	21.06
EV / EBIT	45.58
EV / FCF	140.26

Financial Position

The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.60.

Current Ratio	1.54
Quick Ratio	0.76
Debt / Equity	0.60
Debt / EBITDA	3.36
Debt / FCF	21.31
Interest Coverage	1.49

Financial Efficiency

Return on equity (ROE) is 1.14% and return on invested capital (ROIC) is 3.07%.

Return on Equity (ROE)	1.14%
Return on Assets (ROA)	2.54%
Return on Invested Capital (ROIC)	3.07%
Return on Capital Employed (ROCE)	5.28%
Revenue Per Employee	13.62M
Profits Per Employee	135,630
Employee Count	6,719
Asset Turnover	0.59
Inventory Turnover	1.44

Taxes

In the past 12 months, Piramal Pharma has paid 3.24 billion in taxes.

Income Tax	3.24B
Effective Tax Rate	78.02%

Stock Price Statistics

The stock price has increased by +32.91% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+32.91%
50-Day Moving Average	204.10
200-Day Moving Average	225.91
Relative Strength Index (RSI)	60.21
Average Volume (20 Days)	201,170

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Piramal Pharma had revenue of INR 91.51 billion and earned 911.30 million in profits. Earnings per share was 0.68.

Revenue	91.51B
Gross Profit	59.20B
Operating Income	6.28B
Pretax Income	4.15B
Net Income	911.30M
EBITDA	14.04B
EBIT	6.28B
Earnings Per Share (EPS)	0.68

Full Income Statement

Balance Sheet

The company has 5.21 billion in cash and 48.56 billion in debt, giving a net cash position of -43.35 billion.

Cash & Cash Equivalents	5.21B
Total Debt	48.56B
Net Cash	-43.35B
Net Cash Per Share	n/a
Equity (Book Value)	81.25B
Book Value Per Share	61.40
Working Capital	20.31B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.92 billion and capital expenditures -6.64 billion, giving a free cash flow of 2.28 billion.

Operating Cash Flow	8.92B
Capital Expenditures	-6.64B
Free Cash Flow	2.28B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 64.69%, with operating and profit margins of 6.87% and 1.00%.

Gross Margin	64.69%
Operating Margin	6.87%
Pretax Margin	4.53%
Profit Margin	1.00%
EBITDA Margin	15.34%
EBIT Margin	6.87%
FCF Margin	2.49%

Dividends & Yields

This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 0.07%.

Dividend Per Share	0.14
Dividend Yield	0.07%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	15.88%
Buyback Yield	-4.41%
Shareholder Yield	-4.34%
Earnings Yield	0.33%
FCF Yield	0.82%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	7